Gustavo Viani, Associate Professor at Faculty of Medicine of Botucatu, São Paulo State University (UNESP), shared on LinkedIn:
“Dual Checkpoint Blockade Falls Short in Newly Diagnosed uMGMT GBM
Objective
Evaluate if ipilimumab + nivolumab (w/o temozolomide) + RT survival vs. standard RT + temozolomide in uMGMT glioblastoma
Methods
- Phase II/III RCT, 159 pts, KPS ≥ 70, gross/subtotal resection.
- RT 60 Gy/30fx (IMRT) ± TTFields.
- Experimental arm: ipi 1 mg/kg q4wk × 4 + nivo 3 mg/kg q2wk until progression; no TMZ.
Results
- No PFS benefit: 7.7 mo (ipi+nivo) vs. 8.5 mo (TMZ) (HR 1.47)
- OS immature (~13 mo both arms)
- Similar grade 3–4 AE rates; 2 immune-related deaths
Takeaway:
- TMZ remains standard for uMGMT GBM—dual ICI not superior.”
Title: Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial
Authors: Andrew B. Lassman, Mei-Yin C. Polley, Fabio M. Iwamoto, Andrew E. Sloan, Tony J.C. Wang, Kenneth D. Aldape, Jeffrey S. Wefel, Vinai Gondi, Alonso N. Gutierrez, Mohammed H. Manasawala, Mark R. Gilbert, Erik P. Sulman, Jedd D. Wolchok, Richard M. Green, Elizabeth C. Neil, Rimas V. Lukas, Samuel A. Goldlust, Matija Snuderl, Kristyn Galbraith, James J. Dignam, Minhee Won, Minesh P. Mehta
Read the Full Article.
More posts featuring Gustavo Viani.
